Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MDA-MB-134-VI | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.107 | uM | 14837.203 | 0.0065 | -0.9254 | 1.5334 | |
| MDA-MB-134-VI | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.533 | uM | 14837.203 | 0.0070 | -0.9216 | 1.5334 | |
| MDA-MB-134-VI | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.533 | uM | 14837.203 | 0.0070 | -0.9216 | 1.5334 | |
| MDA-MB-134-VI | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 2.67 | uM | 14837.203 | 0.0058 | -0.9305 | 1.5334 | |
| MDA-MB-134-VI | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 2.67 | uM | 14837.203 | 0.0058 | -0.9305 | 1.5334 | |
| MDA-MB-134-VI | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 13.3 | uM | 14837.203 | 0.0094 | -0.9046 | 1.5334 | |
| MDA-MB-134-VI | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 13.3 | uM | 14837.203 | 0.0094 | -0.9046 | 1.5334 | |
| MDA-MB-134-VI | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 66.7 | uM | 14837.203 | 0.0089 | -0.9078 | 1.5334 | |
| MDA-MB-134-VI | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 66.7 | uM | 14837.203 | 0.0089 | -0.9078 | 1.5334 | |
| MDA-MB-157 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.000427 | uM | 7495.074 | 1.0098 | 1.0167 | 1.1729 | |
| MDA-MB-157 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.000427 | uM | 7495.074 | 1.0098 | 1.0167 | 1.1729 | |
| MDA-MB-157 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.00213 | uM | 7495.074 | 0.9629 | 0.9365 | 1.1729 | |
| MDA-MB-157 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.00213 | uM | 7495.074 | 0.9629 | 0.9365 | 1.1729 | |
| MDA-MB-157 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.0107 | uM | 7495.074 | 1.0077 | 1.0131 | 1.1729 | |
| MDA-MB-157 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.0107 | uM | 7495.074 | 1.0077 | 1.0131 | 1.1729 | |
| MDA-MB-157 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.0533 | uM | 7495.074 | 0.4464 | 0.0055 | 1.1729 | |
| MDA-MB-157 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.0533 | uM | 7495.074 | 0.4464 | 0.0055 | 1.1729 | |
| MDA-MB-157 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.267 | uM | 7495.074 | 0.0357 | -0.8832 | 1.1729 | |
| MDA-MB-157 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.267 | uM | 7495.074 | 0.0357 | -0.8832 | 1.1729 | |
| MDA-MB-157 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 1.33 | uM | 7495.074 | 0.0080 | -0.9675 | 1.1729 | |
| MDA-MB-157 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 1.33 | uM | 7495.074 | 0.0080 | -0.9675 | 1.1729 | |
| MDA-MB-157 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 6.67 | uM | 7495.074 | 0.0003 | -0.9983 | 1.1729 | |
| MDA-MB-157 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 6.67 | uM | 7495.074 | 0.0003 | -0.9983 | 1.1729 | |
| MDA-MB-157 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 33.3 | uM | 7495.074 | 0.0023 | -0.9885 | 1.1729 | |
| MDA-MB-157 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 33.3 | uM | 7495.074 | 0.0023 | -0.9885 | 1.1729 |